NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $6.43 +0.05 (+0.78%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$6.53 +0.10 (+1.56%) As of 09/25/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.25▼$6.6950-Day Range$4.20▼$7.8752-Week Range$3.25▼$41.80Volume11,014 shsAverage Volume1.67 million shsMarket Capitalization$12.92 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases, with an initial emphasis on serious dermatological conditions. The company is developing proprietary topical formulations intended to deliver therapies directly to affected skin while addressing unmet medical needs in patient populations with limited treatment options. Quoin’s lead product candidate, QRX003, is a topical lotion formulation of sirolimus being developed for the treatment of Netherton syndrome, a rare genetic skin disorder. The company is also advancing additional topical product candidates, including QRX004 for recessive dystrophic epidermolysis bullosa, a rare inherited condition characterized by fragile skin and recurrent blistering. Quoin Pharmaceuticals is headquartered in the United States and conducts development activities through clinical and regulatory programs targeting rare-disease markets. As a clinical-stage company, it does not yet have commercially approved products and remains focused on research, clinical development and potential regulatory approval of its pipeline therapies.AI Generated. May Contain Errors. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreQNRX MarketRank™: Quoin Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 93rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialQuoin Pharmaceuticals has a consensus price target of $20.00, representing about 211.0% upside from its current price of $6.43.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.08% of the float of Quoin Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 76.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.47 News SentimentQuoin Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Quoin Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for QNRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership4.1 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Quoin Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $279,966.00 in company stock, which represents 2.1662% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $279,966.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.17% of the stock of Quoin Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Stock News HeadlinesFour Small-Cap Stocks to Watch With Small Floats and Big Catalysts (CHGA, QNRX, MYSE, LNKS)September 25 at 12:02 PM | marketscreener.comMQuoin Pharmaceuticals (NASDAQ:QNRX) Stock Picked Up by Analysts at Lake Street CapitalSeptember 25 at 1:42 AM | americanbankingnews.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 26 at 1:00 AM | TradeSmith (Ad)Quoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin SyndromeSeptember 23 at 8:21 AM | rttnews.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeSeptember 22, 2026 | finanznachrichten.deQuoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeSeptember 22, 2026 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICUSeptember 10, 2026 | finance.yahoo.comInsider Buying: Quoin Pharmaceuticals (NASDAQ:QNRX) Director Acquires $29,992.48 in StockSeptember 2, 2026 | insidertrades.comSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $14.43 at the start of the year. Since then, QNRX shares have decreased by 55.4% and is now trading at $6.43. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) announced its earnings results on Friday, August, 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by $0.29. When did Quoin Pharmaceuticals' stock split? Shares of Quoin Pharmaceuticals reverse split before market open on Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Quoin Pharmaceuticals IPO? Quoin Pharmaceuticals (QNRX) raised $0 in an initial public offering on Friday, July 29th 2016. The company issued 1,292,308 shares at $0.00 per share. Who are Quoin Pharmaceuticals' major shareholders? Top institutional shareholders of Quoin Pharmaceuticals include Velan Capital Investment Management LP (1.61%). Insiders that own company stock include Anthony James Culverwell, Michael Myers, Denise P Carter, Sally Bridget Lawlor and Gordon Dunn. View institutional ownership trends. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/14/2026Today9/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 QNRX's financial health is in the Green zone, according to TradeSmith. QNRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone+97299741444Fax972-9767-8750Employees6Year FoundedN/APrice Target and Rating Average Price Target for Quoin Pharmaceuticals$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+211.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($25.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-489.57% Return on Assets-221.17% Debt Debt-to-Equity RatioN/A Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.64 per share Price / Book0.41Miscellaneous Outstanding Shares2,010,000Free Float1,784,000Market Cap$12.92 million OptionableNot Optionable Beta1.51 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:QNRX) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored6 Elon Musk companies. The 1 FREE investor roadmap to them all.Elon Musk owns six companies, but most investors can only access four. Tesla, SpaceX, xAI, and X are public an...Zacks | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
